Search

Zentalis Pharmaceuticals Inc

Lezárt

4.72 -3.48

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

4.7

Maximum

4.85

Fő mutatók

By Trading Economics

Bevétel

-136K

-35M

Egy részvényre jutó nyereség

-0.503

Munkavállalók

106

EBITDA

2.2M

-35M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+53.8% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. aug. 4.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

26M

321M

Előző nyitás

8.2

Előző zárás

4.72

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. júl. 31. 23:56 UTC

In after-market trading, Invesco Ltd shares are lower, moving from a high of 0.51% to a low of -0.81%. No specific news was identified.

2026. júl. 31. 23:56 UTC

Social Media

Equifax Inc. shares are higher in after-market trading, buoyed by CEO Mark Begor's outlook on strong cash flow and $1.6 billion returned to shareholders.

2026. júl. 31. 23:56 UTC

Dutch Bros Inc. shares are lower in after-market trading, fluctuating within a routine range since Friday's close. The price remains stable in its one-month trading range.

2026. júl. 31. 23:56 UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

2026. júl. 31. 23:56 UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

2026. júl. 31. 23:56 UTC

iShares 1-3 Year Treasury Bond ETF trading roughly flat in after-market hours. Global equity indices are mixed, with U.S. markets lower and others higher.

2026. júl. 31. 23:56 UTC

Indie Semiconductor Inc. shares are near unchanged in after-market trading, following a notable decline over the past month and remaining below the 20-day moving average.

2026. júl. 31. 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

2026. júl. 31. 23:56 UTC

ETF Constituents

Vanguard Real Estate ETF trading was roughly flat after hours, with CSGP, VNO, and IIPR contributing negatively while ADC provided a modest positive impact.

2026. júl. 31. 23:56 UTC

AeroVironment Inc shares are lower in after-market hours, with no specific news identified. The stock is near the lower end of its one-month range.

2026. júl. 31. 23:56 UTC

Transocean Ltd shares are higher in after-market trading, continuing a trend of gains over the past three sessions. No specific news was identified for the move.

2026. júl. 31. 23:56 UTC

Comcast shares are higher in after-market trading, showing volatility with no specific news to explain the movement. Broader market trends include gains in the Nikkei 225.

2026. júl. 31. 23:56 UTC

Correlated Moves

Texas Instruments Inc. shows little change in after-market trading, reflecting broader weakness in the technology sector amid mixed Asian market performance.

2026. júl. 31. 23:56 UTC

Barnes Group Inc. shares declined in after-market trading, showing minor fluctuations without specific news. Asian market results provided broader context for the movement.

2026. júl. 31. 23:56 UTC

Diamondback Energy Inc shares are higher in after-market trading, continuing recent upward momentum and reflecting strong investor interest amid no specific news.

2026. júl. 31. 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

2026. júl. 31. 23:56 UTC

Marathon Digital Holdings shares are higher in after-market trading, reflecting routine activity with no specific news identified. The stock remains below its 20-day moving average.

2026. júl. 31. 23:56 UTC

MSCI Inc. shares advanced in after-market trading, supported by a rise in the Nikkei 225 Index and renewed interest in AI stocks.

2026. júl. 31. 23:56 UTC

Block Inc shares are higher in after-market trading, buoyed by strong earnings from U.S. tech companies that eased concerns about AI infrastructure spending.

2026. júl. 31. 23:56 UTC

Correlated Moves

Procter & Gamble Co shares declined in after-market trading, reflecting broader sector trends as Kimberly-Clark Corp also reported a drop.

2026. júl. 31. 23:56 UTC

Adobe Inc shares are lower in after-market hours, with no specific news identified. The stock has declined since Friday's close, amid mixed broader market trends.

2026. júl. 31. 23:52 UTC

Mexican Inflation Rate Set for Release Amid Mixed Market Sentiment and Global Price Pressures

2026. júl. 31. 23:52 UTC

Mexico's Inflation Rate Release on August 7, 2026, Amidst Global Economic Pressures and Mixed Market Sentiment.

2026. júl. 31. 23:52 UTC

South Korea's July Exports Expected to Grow 0.59% YoY Amid Cautious Optimism Following Record Highs

2026. júl. 31. 23:52 UTC

Rising MBA 30-Year Mortgage Rates Reach Highest Levels Since Last Year, Signaling Caution Among Homebuyers Amid Economic Pressures.

2026. júl. 31. 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

2026. júl. 31. 23:51 UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

2026. júl. 31. 23:51 UTC

Interactive Brokers Group Inc is lower in after-market trading, reflecting the broader market's significant decline and a position below its 20-day moving average.

2026. júl. 31. 23:51 UTC

Solaredge Technologies Inc shares declined in after-hours trading, reflecting broader market trends. No specific company news was identified to explain the movement.

2026. júl. 31. 23:51 UTC

Evolent Health Inc shares are higher in after-market hours, rebounding from nine consecutive daily declines despite remaining below their 20-day moving average.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

53.8% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 7.29 USD  53.8%

Magas 11 USD

Alacsony 4 USD

8 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

8 ratings

5

Vétel

3

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat